REGISTERED COMPA14Y NUMBER: 11943477 (EngId and Wales) REGISTERED CHARITh NUMBER.. 1185091 AtKIIthQ Rnondal StsteThnts Fdlb¢ular LJrynphorn4 Foundlon {A Company Llmlied byGuarantee ACWJ2VS' 2810912023 COMPANIES HOUSE A75 Hwne5 Watt5 WC1X 8TA
F114•1 Lwnphcffta Foundatlon Contents of the Flronelal Statem fortyear enoed 31 December 2022 2 to 7 8 kn 10 11 Slat•m•rt ¢1 Flnandal P711¢ 12 13 14otts to the St#t¢m•iii of Cash Flows 14 Wotes to tht Flnandol *alem•nts 15 to 22
Foll1• LPhOa Foundlon Reftle and Athilnlstr4iNe D•talls forthÈ year tnded 31 Deewnber2022 Tfttstees Lwd J N Mthls01 Lady N S VS0 PmVTffiP AWtN J J Pojrfey lapwnied 1517f2022} Dr J W Swnon5 laFpJffti•J 1YTf2tr221 s73 Tlwb¥lds Fload WC1X 8TA Reqlsttf•d eunp•ny nwnber 11943477 (ErWwMI •vJWales) R•glsternd ettarlty mwnber Audbttrs H•r*sW41s Oenwent Hcd 69-73 TheobAlds Ro•J WC1X 8TA FI1
Folllcul¥ Lymph¢• Foundatlon Foiiicu homa Report oftt TnJst•es The truBttts who we a30 directh of the dwty the purposes d Ihe Cl¥nlEs ALI 2C(fj. th•r report the finaKiel st•txenls ol the rthnrity fLY the Yew to 31 Dwiber 2022. The trustevs have adopted the prw$ions of Accounting and Reporkng by Chriie5". Statwnerf of RmiMlJed fvaciKe zFfdicaNe lo th8ritie5 wepariTro lTrwr ?oUnt$ in o¢cLYdanre Trwrth the F{la1 SIrd the UK and REpublG ol treland IFRS 11Y21 (effective 1 Januffj 20191. Objectives and activities Our rni5sion 15 to help those +Aith Fcdli¢Llar L)c3. a Clty bkoj cartw. wdl and gBt well byfindino and Ilmdinu the best tolknd breaklhrwts tr1 (zTrJe hcttl [Staj and treat 0jrth.. We provide Follrultsr Lymphoma fooJ5ed Infornti resourcu f(Y to SUre "¢Al¥. are •1 th hE#rt of the search l¢y bthr trtalmenls (#n. More Ihg ¢hari&e5 otriethes aro r85tyKknJ trJ F&11•r Lprn iThJudiTrJ sp¢ Ihe estsbhslwnert of * wrteffl ¢11¢ to and ¢n r8sear¢heT5 lofocus on prvspectyv• Gures. patient rTrrnuThbe5 an¢J •14uatiry the crf patit reFuled cAcwieson current Ireatments ¥de effects to assst dinitians and paknts. To imwove hea#h t¢Tres by way d 51inul"r4 researth •xl of ))m¢Mentsry OxditTh$ to supplernent Mal treatrnent. 2. Achievements N¢w leadersNpiogulde ¢wrmtssion In Juty, we wdryyne(l att4)mphshed CEO K2t• RfrJ•rs to leal ow rxgarozatKffj into the fvrtwe. Kate brings eXceptical vision d expertsse to advance our stratèJK diOn th"vÈ rn10n IC9rd. Her and havg u$ pc4 for oven urer adevemeffls ahvad. Eslabllshln9 esteemed adv1$ bftts Rwnisino the importance crf v¥S¢ persFecb'ves. we estsblshgj nv Life sa.en 8NI lYnphl IrlonTrali¢s Aig¥isory Boards. These boar¢Js pYov¢de invaluatle gudance lo our research dev)menl inits'ab've5, ith 8 fctus on the PrKisb?n MediGin• Prlyrammo. Ther m.5(1ry • help wkxe inrthats'vo approach85 to advlA9 ¢xr understanLlng Off1(#¥ lynpl1& Strenglhtnlng our boanl of ¢nJsthes We warmly wdccffled Jess Burley and knatrAn Snons as truSte•S in 2Wf2. Th•ir kned nd eyperienc• furtW enrich our t)ard and cL¥itriMe divEtse tyowl rMIsS. Amiounelng Inaugural CURE FLAward rKlpnts In Decembtr, we marked 8 si¢an• ffile5tone by ffitsi-ever CURE FL Award recipien15. ath1evnenI signals rnearnngfvl progress in our cunmilmem to acrekrate ler¢h and firKI a ft)liud¥ tyhla VATe. The CURE FL Awards afe not yow typG#l they 8 catatyst chwe In fdkLd¥ researth. Our aim is to a¢xelerate breakthTowhs dwect pati&it benefit le6t r¥811t lIt transorms Ihe FL landw2p8. Thr¢xJoh ¢ollabcKaticfi, we are bringing re5earthers l(gth. ¥h•rity irtsig14 ¥•h'ng ¥lpa5. ar tsN¥edibThJ irnpxfful thstsweries for FL pall1$. Connecllng llh global experts alASH 2022 Ow we5ence at the AJerin Socjety d Hawnatdg3y IASHI C¢18Tt pmide&J an impa oppytunrty t¢ Lr1 wfth the lymphmia c¢mmurMty. We ex¢harged inswJhts. forged ¢dabcration%, and shared ourdeth'cation to a(fvanang IphoMa knowfedge and patr"t A¢ce$ Inthau¥es. We also US Ills <wyturllty t4 to Il l¢Jer r•Tth e<jmmufy ourwork an ts PMP. 3. Strategic report Tho Fdl¢ular LyThphoma Foundaiioft 16 an wrtemth"(ml effcrt b) ffiThJ ac(4w*e cwas and 6F•J tha d•lNWy ol we9¢n.b?$ed Ireatmwrts tsthis IrtUe-knMI cancer. The Follicular Lymphoma Foundation 417 Finchloy Road London NW36HJ FUMiRAIgNG HEliULAIUR
FOkr Lymphma FoUnon Foiiicu homa lorthe yw end•d 31 Oecemb•r 2021 The Foundalion launched pUrtY in P4)vember 2019 •)d Ios been Iwjsed de¥elwThJ Its Strat Ihe Iramewuk fry a hugdy prLywffie oflwrk. None oflfvs have possitle •trthttt suPFt the l¥JThd cl 1th"d$ WI l¥e donat to the Foundab"cffj to help athie ow 3.1 Charltable activities 3.1.1 Strategy Over the ¢ourse of th8 ar the FLF hame5svJ its to J•lcp a apP(b The Foundation cfeated a pkn ba59d ttn trYJ Fqlars: Pilar 1.. The Patst & Prerasion Me(lirine Ftrcw8retts hamess of WBnts Ihe patMt rUrity inthe develoPnrt Dtures and nvAf wsion medrine aPwDgd. F118r 2.. The Targeted Accdwated Reswth fvw•iYn• kn irNest tyly fv mc41 prL¥ni8WLg internobxd FL res•arch dirAcal lriaL8. 3.1.2 Partnershlps One of the FndatiOn rAre WWK4Fdes i% kn •vtyd ar bir¥ •JdtrJ value to lh¢ by Fqrtnerships to ws"ThJ wowime4 drv4e better A¢5 ryeate imp8L. 3.1.3 Infomiatlon Provlslon and Publlc Awareness Ralslng The of Iho FLF rnsed aWarW of Ihe the public arbj hdpgd link people living vrith FL ith sour$ cl Ydrrntson and supFtst As part oflhe laun¢h the F(d0C devdoped a nvw webste 85 8 Srte ofinfcffibon FL patients and a mora edi¢aied Patient Hub FL Patients and famlies. Ttlls $ It Myld3 fifst websrte thth¢aied exclusivdy to Foul8T Lymphoma. 3.2 Financial review 3.2.1 Financlal position The Fwwncaa acwJnts 12 pwKrfJ shryw a d¢ of t223,fi and lh• Ch"ty is well.F#)5LThd b) iweas8 ils •¢tie5 in the fulie. 3.2.2 Reserves pollcy At 31 Dectsnter 2Q2, reSIrted regeThTes were £1.191,W21 resbiLtyJ reserve had a nè>tNe balance of £16.401. The tharity isexpxtingto £2(m).0 ofreslrthl ir(Mel 2023 dearng nryab"v• balwt• of£16,401. The orgwisabon operaies ith lin11 ovetheads. The Tne$ have detvrnid Ihal th& r8S8r¥es twgel should be at the levd of 3 months, •4)eC expendrture. 8udgetaJ eXpeThJire in 2023 fiwLial year s in excess of £2m. and the Truslees ha set a twgded resaNes fwe d £SOQk as at 31 Oe£em 20t2. 3.3 Going concem The Twsiees t¥Jnsider that tt is 3ptYopriale to wep8r• the stments a gory concem basis. Tr gL¥ng cLCeM assurnpton Is bas on an exisbng 0ft aryj In place covenw penoj to Oectrnbef 2023. A nwl >year twdgeUI(x#4st 1$ bwj draft•J whKh radLKe extwnal w5ts ar vol sUbdaallY rwjuce annud d•fiats. In a4dth"on. the TNslees to mvesb"gat¢ to enhance th• lonfrterm sustw"nalilty of the charty an¢J identfy those areas where thE perfo¥marYx Gan b¢ imprrN&a. ilh xtiorts bu.ng tak to rthGe defiats. The e5tablishmenl of a SIled teurn of anent ejnployees dem¢)nstrates Folivjlar Lymphuna FouTrlation'$ nmitsnerrt to the opwalion oflhe Charity a$ 8 gclng ccrfwn. As a res1 of thèse f8dty5 ¢he TN*s eonsider the goino onrem basis to be apprDpriaie. The Fr>lli¢ulaf Lymphoma Foundation 417 Finchley Road London Nw38J FR UNCTrR41ShNG EGULATOR 410)203d17es83
Folllcular LphTra Foundthn
Folllcu
homa
Report dth• Trustees
foritte y ended 310e¢omber 2022
3.4 Principal risks and uncertalnties
The trustees have a duty lo ldenb.fy we4V the risks trj wu"ch Ihe charty is 8j tr) wure apwo&Thte ctffilmls
are in 8¢¢ lo wo¥Kte reasonatd8 a$9alKS W tra1 aThJ
The INstees have assessed risks to lMch tht is e)¥os¢d sati5fivJ that systvrns in pla¢e to
mthge eXFxwe to stth rnw risks.
ProGedwes ar• in pla lo ensure compharte ith W aThl staff. vc4unleern. dients. and vitor¥ lo the
gars2tb)n. The Chwity h•$ th appwatt l¢vel of insuraft¢¢ to meet rts otgatths fft respeci of ¥nploy¢es and
3.5 Future plans
3.5.1 Plans for the next 12 Months
Our orÈ8s offrfftts".
Dellyerfng knpa¢i through fvttustd $T¢h.
¢In9 thg qap6in FL re5earth and dr dv4fjlpwnt IlY0h lh• dual arvoath ¥s1On'01d•nc•-a6•d,
FL infomab'on and invesbno In the most prrJni%ng uJattve research.
Devel¢Jpirw new treaimwty arKI oire$ 10 FL patwi$ ty>t ¢Yeating a phw•y vith rapKI 'benthto.bedsMI¢'
devekspments.
Collaboratlng ¥Ath lh• b•st
Rdath)r%h'ps are key to Ihe success rf Ihe dwity. We map eyi51iThJ aTrJ nt4V Tunite5 for pthershiF6 at
on intemats.ond Iwd, bLyIth"ng rm uihc41 h"rs ewrt¥. Sci rexarcher5, •nd
philanthrpp¢ domrs.
Growlng luntha151w lfteom•.
Raisiry tur5 is e$11¥ kj en5UTing w stratwc mwjl1 prCwrrS and that we havE the ffinon(ial
re8ourc¢s avlabl• lo Carry the necewry scienffi¢ research io find • re. Wt stn.ve to mantain and buiF
Follleular Lymla Foundthn Foiiicu homa R•port orthe TThstees fortmyear end 31 Oecefflber 2022 3.5.3 Targeted Aceelerated Research (TAR) programmes One key area for the FLF is tttw8pw&c devel0m)l iThbab"t&S. ¢an aanC&y and tranYatsor4 TeseaTth. ro date. tho kYLyess in th¢treaknwrt d FL has bEen fntstr"Wy sluw, ilh fvndiTrJ aThl Our 8Uito of Target Accdevated Re58arch ITARI iThbati¥•s ain tts mako al.¥0 IheraFqes awilthty to FL Ptts •5 8¢on as poss4e. thjr TAA Fwammes 1ce ow wwess tiyward% our ff56K¥) by investing thv tru"ghest ¢olibre resetr¢h pronisng iMjrate to Ihe patent (CURE FL Award51'. ¢Yeating aoteoc Pther5hips wilh top inv¢sts"galor5 and insl>tths artyjnd WlId Icentres cl Excelkncel: ar¥J enS1Vj we dony mts$ out OA urnque hiih.n$k, hirrd 0ppwt1me5 IOFfthmty FuThll. CURE FL Aw4nls Prngrme The CURE FL Awd$. laurK&l in 2022. we a uniy rtsear¢h b¥ntyThJ Ic98th4¥ scaenli5ts re3earchers world%ide. Tlyouth irw)OVativti iyoiecls, wo arn b) siftty advan d4r41 lrials and effecttve n therapies fLY pabents. Addresslng the need fvr more Tollkular l>Thphoma Rsearth Fdlicular IphOMa 15 clten overshajowgj cLarS to cther IJITw8$. ts 8f¢yww progrlun and trtal Mtetthe 2022 9ran¢ees In cdlaborAtion w• ¢¥thlLv sdKlod kY¢pJsals targHl•ig k•y IdlipJr tymphcffla n8•J6 it"%ng w.ent inleFe5ts and diThcal aFf4Katif. After a knonth invc4wfftg xperts and pati¥ts. w• I¢e the most lng wr¥ects cxrt 0120 We are tmlled to introduR our first tywtees and the excits"Tha resethrth weas. &h has been awarded up to $9]OK ov fvxs ye#ts. bwnrring Oecembor 2022. Tru$ sbJnth¢art in¥tslm•rt m¥ks an in1 stride tard ¢w rn1£. The Foll1cr LyThtoma Foundabon is honoured to surport the CTitscat M)Jk of the fdlowng pioneering researchers vkno were sdeeted as the inauLwral CURE FL Avrards grantees in De¢ember 2022: n5¢uldo endel ori Sloan Ketterin caer '. A rw $6gr•l me¢haThsm IHVEMIBTLAI abnoThal in 90% of FL cases and imF•rtant in Ihe gernss ol FL has beem idwtfjied by Or d his wp. This make5 HVENVBTLA a IN'-Value t¥rW 5Fe4fi¢ to FL. CAR-T cd15 that atlAck 8118 cdls are an exciting ntw treatmerrt for FL. Tlws use CAR.T in a dDYerenl way, lo S[fical attack t1"S FL4pfic pathwBy. The goal isto Iw¢ • tri•1 ofth¢s¢ r#)vEI CAR.T¢41s4¥th fty patiwls by the the wt wod. Dr Joshua B Icahn Schcd of Med'one at nt Sm ' US.. CAR-T eelL% •r * excellent treabheTrt fcf scffie patients Wth FL but do not rk fw evuyone. Dr W4. in immwK+lherapy of and hi5 te8m hèvè that by4#nder c811s that th) eleSS the CAR-T l¥gBt we one mechanism of CAR.T resislance, d Ihal they may have a to overcane Ih"s. Th•"r Y may ll 11 lo a &"nKal knal of G4R-T given a drug tthat wll enhance the kilir#J d these bystwKler cdls. 4nwo%ing outctsnes fu patients. ". Dr 8Wln. an expwi bK4oJy, with h dinul ts)Ilab)rat¢rs. ill r£Idu knas (3>niiThng W9Wic-targeW EZH2 ithiL¥tot5 immunolherapy (CAR-T or btsptitific anlbothesl. or 8poOosiS.t BCL2 ?nit¥try>. Usjng LM1q FL mouso models and pationt sampl85, she wll stth 0.3th0n5Oflaf9al•S thwapos Wth imrNncther8py. inc4uth'rvJ imp on bDth FL B c•116 and its mi¢xoeNmnmrt Tho is derm to imF¥¢walhwapy in FL Leading this Spani$h 0p with exten51ve dinic ewence dv4eloFng CAR-T Ir¢alment Tlw dewl¢)p new generation duaktsrgete¢l CAR-T cdls, ed1$ Ihat crfy lyThphL¥na felL% tArt the swrounding Micr0enr)rMenI that helps keep FL cUs ahve. Thv4 W 10 havè• ofthe b85t CAR.T reaty by Ihe ofthe gant pen¢>J. The Follicular Lymphoma Foundalion 417Fsnchley Road London NW36F ¥J¥•.Iheflf +44101203d178583 FUWRAISING REGVL4TOFI
Follkulx LyTnph¢fft• Found
Foificu
Report of the Trustees
forthe ytrarended 31 Deeember2022
Ac¢elernUng progress and Impact
8y allocatino $2 million over yea. Ihe ¢VRE FL Award5 wopel u5 doser to b¢tler t0$ and 8 ojre. We aim lo
elevate f141ieLa8r fymphoma's $Jn8n in drwJ devdcpKni and t•e t•.1we therap%8. Ow swl k to bring hq>e,
opporturilies, and ltsCa1 treatrnent insigtrts lo patienls dIan5.
FLF ¢entr•s ol E¥¢dlence ICOE)
The FLF proudly Pres15 the Centres ol Ey£dlerM ICoE} wcywnmtr. * (¥wng init"Ve that fvges pwherships with
major acad1¢ aThJ research institltiors %•rthide. Tlis wogramme harrsseS Ihe o)leclive expertise cl estewfitr
instrtuttws. SPnVbg vari¢x th6(iFdin%. tr)
Folkular Lyrynphorna Found•tlon Folllcu homa Report of the Trusttes forth•year ended 31 Dernber2D22 A¢nI6[V &andwd5 (Ved Generalty Awted A¢axnbThJ Practi) Indu¢fty Rewl#Yd Standa 102 Yhe ReFu'ng Slandard aprabte in the UK Rewbé¢ ¢4 I[dan. Ccffiwy r4uires the Iruste85 to prepare fin1> atem•ts knr each fmraal yr tich giv• a tvJ8 and faw wew ol the 5ts1e ol affairs cl Djngany Ihe }r1j rexM#ces akWiGabDn ol resources. indudiThJ the income and eXpdthre, Gl ihe ch8nl8ble lmPanY ts th8t [. In Fwaring those finarL1 stsIents, Ihe tn45tee5 are 1•4uir8d to Sdert $urtat4e kxliries ¥rKI aswy than w5knty. Obs¢rve Ihe melhods aTrl wtriupTres in the Ch¥ty SORP. Make judgents esi¥nales thai we reas¢¥MNe and State Whetr 8PF4icablè standards ha¥• fdh7w¢d. bject lo any departWe8 di8dos•J and expl8irl in Ihefih2n¢ial staiemeAts. Prepaf• the ffinanod statwnenfs ¢Jn Ihe crKern b$ unl¢ss it isinapprwth b ryrne th)t Ihe chaTTrtable ompoThy will ltin in Imwess. The tru4e8s are r8$w$lble kerfiiiio propw attOthlirvJ Trc•xds dis(1058 wllh reasonable axura¢y ai any tine tr rinanLI81 pos"0n of Ihe tharitable ccffjpany and lo enat4e them to xure Ihat the fih8ncial atements g)mFly wlh the Companies Ad 20CA3. They are aso reswLEible lor safryuardmg the assets of Ihe thilatle (wiparry and h8n¢e frr tsli reasonable stW5 for Ihe prt and detectK)n dlrdud aThJ ottw iffewlwi1S. So far asthe trustees are aware: There is no relevant wJdit inlcthiakn dwi4wecoTrparf5a510r5 are Uore.. and the trustees have tak al 5teF6 that Ilw to have ten to rn8ke of 8ty rdwant 4uth"t 4. Auditors Report ofthe trustees, inDwats"w a strategr reF<rt by ord¥ rfl bxrd { tru5tea. as ihe compgny thetor$. Sep 27, 2023 . and signed on the boaryl'5 bthaff by". MendqM4hty15op27,M23WJ3GIIT+ii Lryd J N IAenddsokn. Trustee The FollicularLymphoma FIndatiOn 417Finchley Road London NWJ61.IJ vw.thefif 1441Vl&4JU411UJ FR FI IFTh&ICJNr ktiLILATOR
Rep1 ofthe IndepenAutQto the IAembers of F11¢ar Lnph¢m4 Foundallon Oplnlon We ha avditett Ihe fjnarKaa statements Fo#T L>ryiwhtyTr8 Ftsjndatth 'chwit8L4e D)mp8nl ft¢ year ended 31 08ber 2022 W1Ch comprise Ihe Staton1 d Finanraal AcbTrAties, the Slemenf of Financ441 Pos"tun. d Cash Fknvs notes to the st8tèi%rts. ¢nduth'rMJ a wmm¥ry tsf signrftont 8cc>Junb"ng pdiue$. fmanfial repoth.ng framework that has ap11 n thar preparatrth) 15 apiCatIO law and Unilod lfjnud Accounting St8ndards IUThted Genwally krepted Ac¥3)unting Pra¢"rl, Finanoal R8wtirvJ Slandwd 102 Tr R¢portsva 8laThJafd appbrth in the UK and of IreIar'. h) our Ihe finart #atents." give a Iruo far View of the State d Ihe chanlatle affars as at 31 December 2022 and ol lis inC1r r•sourcas and apr4¢atth trf $¢e$. indLwth"ry rts inCLYna evditUre, for year th¢n •nd¢d", have prOplY prepar•J in acwdaTr2 urt jd Generally Accept•a Acuunbrvj P'Co. I1UdIruj Flnanc•a ReporDng $18TrJ8rd 102 The Anar1 ReFabr¥J SIdd apl41cab in the UK and Republrc of IrdaTrd': nd . have be4n w¢F4r¢d in xc0rd1lh the wirements rflh• Crrnp•iDes 21Th. easls for Wnlon W ¢ondLKted our aj(¢ in acc4)rdaw Intwnal¥M•l Slarkaards on A¢"ng IUK) IISAS IUKII and ap1¢at law. Our respMbilib"es lkne staTrJwth are lurthar descnbed in the A1¢5, reSpJn%b48S for the audit of the financial $taiement5 StIOn ol trjr W We ir¥je>weTrI cl Ihe ctsit&4e 0)nY in acdarts ilh Ihe ethical raqurements that ar• relwwt to ow udit of thg firontia in tha UK. thè FRC$ El¥cal Standard. and we have luffi11 ¢yJr oth¥ ellY"cal resportst"lths in (¥danCe wilh Lh requIrern. W? bdi¢v¢ that Ihg awtht evidence we have Obtain 15 and apprcpriate to pttyKl¢ a bas$ ow ¢•rrion. Coneluslons relallng to golng c41nC In 8udibW theflnarKial staternents, w• have conclLwJed thatlhv Ilute< useof caKem baws ofxcwiling in the preparatK>n of th¢fin8nual StsIen1$ is apwowate. thal, indivh4uaUy ty ¢dle¢bvdy. may ca sgrmficont on Ihe thariiatrle c£thpanYs ability to ojrknnue 85 a gThn9 concem for a pwiod ol at l•a5t twefv• rnorths from finanual statemen1$ 4t0 4ulhoris6d kn issua. Our re5p0ns1bfliti aThl the respo1"1$ of the trustees ith re5Fttt to Conc are deSbed in ts relevant sed)ns oftPAS rw. Olh•r Infom)atlon The trystw are re8F4MsiL4e for the ther wrfiThalion. The othtr ¢L¥ryrises the Inf0Th induded in the Amual Report, other the slaternents ow Rryort dthe hJe4>uwJentAuditors Ihereon. Our opini¢Jn gn Ih¢fin8noal statements does the Informats. and, to the t¥iert 01hels8 8xplKi Stat in our ryrL w dc not 8xwo8s anyfr)rm ofaG9Jrarts ccfidusion therTh. In connecbon wth •wt ol Ihe fmaw?al atem¥bts. nSitltY is lo tr other fftfomntro) and. In ¢thg $0. onsider t*ther the othw Infi¥rnatr'on materialy irKODsi5tI the finanL7a statuneTrts our knedgts obtanffjd in the audt othemse appears to be materialty mBstated. W idenlfy suth matersal Incorstene$ or apparent matertal maMients. we are reqlqred 10 delwmine wthelher this gives rlse a merial M[aleml in the fimnraal statements bhemsefves. W. bas on the h•Ye p¥lmtyJ, we Cdude tha¢ there is a material misstafwnenl ofthis ¢th¢r inforniation. * a f¢qLAr to repxt Ihai lacL We hav noYy'rv4 to r¢ptyl in th"$ r¢gard. Oplnlons on matters pres¢rflJed by th• Comporfes Act 2001 In rJJr wnion. based on the work uTrjLYtak in It ofthe at". the infrnnaD"rffj given Ihe Report of the TnLStees fe finaal yer fry Ihv InK•l stsli¥htyts r& prepared is ccfflsistI ith theran¢jaI slunen15", arnj . the Report ofthe Tntstees has been prepared n ¢darth apFknLleleoal rrfu1r*.
Folllwjlar LPh¢ma Fourthlon Matter5 on whl¢h we are reqred to report by •xwJon In the [ht olthe kntyed98 undersi)thr4J of the thariiable e£rfnpany * tts envyonment obtamd in ciwrse of Ihe audit. have not idenithed materid misstatemi¥iis in Rewi of the Trustees. We have t"n0 to ryrt in respec matt#5 the Ccfflpori85 2006 rquires usto report b) you ow opini¢m". br8nches not th$itsd ty ". the finanaal statwnents are not in aWe•nl71h tr acctyjrdty reAds atsj ffAum& certain th¥doswES ( IDJslee5' raUneratiOn speofied by Lqware not made.. w• have not r•¥ all the •vplanAt"o wo fmuiroforw •4bJiL Respon51bf111kn5 ¢1 trustees As explained more fvlly in the of Tryst¢es' Resp51"s, Ihe trLotee$ 17kn aTe dso the dYe¢t¢Ys thÈ charitae company for Ihe ptswes of cclnpwy bwl 8 resP11e for the prwrabon rf Ihe finaniyd slalwnents and for being saJsfied that Ihey gNe a Iwe la"r ar¥J forw iremal cc¥fc4 asthe trustees detennine 15 neSSary to engblè tht prepar&tic offi(481 statwnwts th#t We free from misswnL thether due to Iraud or err+y. preparing the sl8menty in• InJst•es ¥ fty assessrwJ tr ¢kn•rt1o ats.ltty to ntinue 4$ a ooing o)nwn. Osdosir¥J. as appIe. mters re18teA to gung CO and usrd the gcwy c4ncem ba6is of acMunb"ng 1•$$ th• tt$ either inleThJ to liquidate th8 chalitaa ccfflparry or lo caasè opeAtions, or have no realisb"¢ alterrrttre ixrt to do 5 Our responslbllwes lorthe audlt of the flnanclal siatements Our obiective$ are lo obtain reascffth asswarte eth•f the Slalaents a5 8 fr•e from material mi55tato)ienL trTrEr due LY wr(Y. and to a ReFyt oflhe IndeperthN Audth that includes O opinion. Reasonable 8ssurwKe is 8 l¥gh lÈvel thl assurance, IM is rt a guwanteé that an 4rt Gonductd in 4¢¢4rd2nce with ISAS IUKI will aways dei¢¢t a mwial mi85tatwnent ¥kneh rt $t$. Mtsststwnents caD srise fr¢)m frthjd or wror and are u)r6iderèJ motenol rf. in¢¥klualty or in the aggregète. try could rea50naW be exFeCted to inflUere lTheoUrib¢5. indudiTrJ frawl. •e instances ol with laws wl"<¥)s. We d85ign prDcedure5 in ITh7 ith our respon5ibil'th. jIbn 4tA)ve. to de fflaterl in respectof Irrla.e$. includina tratsd. The exlent l<¥ tyJr woGJures are capat48 ofdete¢iTrJ irr•aul¥ilies. Iraud is detaled bdtr4.' W• ned an und¥stsndng Ihe Wl rwAaW aPFINe trj the ccffiY the lTrJLStry in whch it oper8tes, 8nd cons¢der•J the rk d acts by the ctynwy thal c<ffjtrwy Io aFph¢8t4e law5 and regulatioTh5. induding fr•Jd. We disc&¥ with the 01r10[5 the psiues and prowjures pla regardir¥J comN8nCe with 18WS and r8oulab"O WB discussed Ihe authl team the KlenbfiÈd Laws and reguLgb"cns. aFwJ rwnained alert to any indi¢ats"Ims rf n-cCffipIiM. thjnng the aL1 we fcthssed on xl tmlith reasony be expe to gNe rise tts a malerial rn155t•twnent in the financ4al slatemenis, induth'ThJ, tJt nol Ivnited to. the Ccfflparits Act 2th26 and UK tax l•JIatIOn. Our tests induded agng Ihe finanoal stalement dsdogrn to ur"ra supptykng drenlèti and enquiries ith management Our procedurey in rdation to fr8ud Ind t#A wtre Tr)t limrted t. NlfeS cl rnarwient lthether they hbv8 any kntrAedge of any aclual, SU5Fecled or alw fraud. •nd drscu551ryts •norysi audit regardw risk of fraud suth as tsprKJrtunibes for fraunt Manw)atn ol ffinaTrial ststents. We deternined that the wnopal r&ks re18ted to posting manual joumal entn85 to maniwlate fin¥1 p&furnat aThJ managErnEnt ts"a5 Ilwough judgernen15 in accountir#J estirnates. We 8150 •Jdressa the risk of m8rm•A tywrid¢ IAtwft ¢wtrds. iaun9 $"Tha Ithjrn# and evaluating whether there was of ba5 by the drctty5 Ihal rfjpresfjnt a risk rf m8twid misslatent due tolrnud. B¢eau$• lh¢ inherent lxtsti audit Ihwe 8 risk that Trll do11 11 irregulariii88, induding thc leading to a rnaal in the fir4n(a¥ Slatern fx rKYrff[IIanCe 1h reguLqD"on. Thls rfsk Inueases Ihe more that ith 8 Iw or re9ati( 15 frcffj the venls and trm¢b"ons ffecte in the finanaal $taternent5. as w• 11 be 5$ likdy to becthme Lif instances of Tlp.0T. The rsk ts 4$0 weatsr regrdin9 rregularibes cccJJrnrvJ due to fre rather IIMn effLY. 85 vNdves IrknnIkn kgery. Ojllu cffiission Orm1$repentatiQn. A thjrfher descripkn resptsnstrflibes audrt the statTrts is the Finanoal Rerng uwl's w8tsite * www.trc.ay.It51esTrilrthS. Tli5 f(¥m5 Pat thf Rel11 rf Ihe 11e[K[errt Audrtors. P•9
Follkndar LJThphoma Foundatl¢)n Us of our regon Thls reFUt is made sdely to Ihe chafitaile ¢t¥np8nf$ mwbtss. •s a b(Yty. xc£¥dance ilh Chapw 3 of Part 16 of the C¢Ynp8nies Aci 2005. Our has undert8kan so we n¥glrt state 10 Charitab companys rnembers thos8 mott¢rs we 8re requir8d io slat& b) lh in an w(t¢X5' reFYt and for no cthw purpose. To est exlent plIte by law, do aewl trf assLxnÈ $Fltlty to anYe thÈr It7 Ihe Charitab cunpany the ¢h•itaNq wnpanl$ fflbs as a tdy. au(&t l(¥ LY kn Ihe wrJrwe havg fcfft. J#MWils ISeni<x Statutory for and on behaN ot Haines Watts Chartered AcCltants ar#1 Sta¥1 Authlty New Dvwent House ew73 The<thlds Ro London WC1x efA Sep 27, 2023 P•Je 10
Folllcular F•vThdaUon StateTht d Flfiandal Acllvhles (IncooralIng an Income and Expendture AcwJnQ for the year eftded 31 D¢earnb¢r 2022 2022 To¢al 2021 Total funds Unreslrl¢trd Resirf¢ied funds fund Incom• and ndoTnents DonaltQn8 and leg•ty¢6 1.984.641 2.184.641 1,678.785 Inveslment iTrxme 1.619 1.619 37 Toui 1.9W2eo 1.678.822 Expendlture on Raising fiJrK15 330.453 1r,992 Charltable aclMtI•s DireLI Expendibjre 1.713.3 16.302 133.677 216.401 1,929.7J3 16,302 133,677 457.358 27,1S5 Supyt t4sts 2 410 165 INCOMEIEXPENDITURE> 1207.504) 116.4011 1223.9051 1.043.¢Jg8 R•¢onclllaUb)n of lund5 Tota I$ bro1v1 fcyward 1.399.425 1.399.425 3&S.337 Total lunds ¢affl¢d forward 1 191921 1 175520 Contlnulng opeTatlon5 l income anil expdiknx• has arisen 188. 2023. Rtstlkl ftHS R85tn"cted Dofial fwKls cam•d fiward Lrf£16,401 bÈco¥er&l bytohYhAtJY multyear •ft. s*ond p•rt duè kn 2023.
Foltlcdar LornI Foundlon IReglster•d ThAnlxr. 11M347T} Sl•temerrt of Flnandal Posftlon 31 Oeonber 2022 2022 2021 Flxed a55ets ran4 ¥ssets 7,033 12 57,7e6 22,775 1416 474 Cash at bank 1,439.X 1.439,249 Credltors Amounts du• y 13 1270.7211 145,5201 Net cyrrert assets Totsl assets le55 ciirrent Ibthlfts 1.175.520 1.399,425 NET ASSErs 1.399,425 Funds UnrestriLxwJ fun(15.' Genèral fund R8$trict¢d lynds Reslricted 16 1.399.425 Total fvnd$ 1 175 520 1399 425 The fin8nrytl atattsments weYÈ apwoved by the Bowd rf TnHlees and authLYxd IDr issue on .. and ve ils behaff ty. Sep 27, 2023 IIFrtdd50Thnl5qp27.J0230a".33GMT•Jl J N MoTrJelsth. Tntsl¢g Tr nths part rfts•fjrArK siatemtyts PJ• 12
F1•1 LnphO F(pundatt•n Statem•rt of Cash Flow5 for theyearended 31 December 2022 2022 2021 NDtsS $h flows from op•rallng adltthlts Cash genuaw 48 4521 913 908 N¢t eash (Us iiywty.ded ty operthg aBbMities 913 9)8 ¢H$h Ilows from Invesllng admues Purthase Oftarvibffixed assets Intwest rec4v¢d 14,&)01 1.819 15.6471 37 Net cash u50d in ¥hv¢sb"ng a(*"viSes Change In cash aTrd cash ery1Val In th• reporung portod Cash and Gash equlvalenls at the beglnnlng vf Ihv WEPQrtlng perlod 151.4331 8.298 1416 474 cash and cash equIvafftts atthe end tht rèponjng pertod 1416474 Th• rnt•s •xm rtore Trial ststtrnents Poge 13
Follludar Lymph(Tha Foundatlon Notesto Statanent <4 Cash Flows forthe yw endtd 31 (kteml>er 2022 Recon¢lllaUon olnel leyj11knCtyDe1nVI c45h wrailtvj aciivlti 2022 Net lexpendturelllKome forthe repwithll rfo las per Ihe Statement ot Flnan¢lal Acllvlllesl Adlu$tments for. Deweuation charge5 kntvest reeaved kncrease in debtU8 12fJ.9051 1.043.088 1578 1371 112,8641 11,619 134.9911 Net cash {used Invwlded by opernljo 913.908 Anatysls ofcash ush equlvalents 20 2021 Notice dryxits (less Ihan 3 mcrtP£l Oeficrt in resiricaed reserve 1.381.442 164011 1.41Q474 Totd cash and (*sh equwth 1416,474 The chaiity is eXptirj to Terni £2).0[• of r•StrKtedwMo 2023 d14 bal¢• of £16.401. Anaty519 ol ¢hang•s In n•t frjnds At 111r12 Cash flu At 31112ra2 Net ush Cash at bank 1.416.474 151,4331 1.365.041 1 416.474 1 365 041 Totsl 1 416 474 1 365 041 The rntes fom) part offheselrArKlaf slatan&its Pap 14
Folll¢ular LlPhIa Foundatlon for theyear eftaed 31 Dettrnber 2022 ACcintI Wldes Basls of pr•parfno the lIr1•1 statents The finarKI slziunents d the chaiAaL4e rJJnwy. a puta¢ trrt enbty under FRS 1W2, have been prepared n acry)rdon¢¢ with the Chils SORP IFRS 1021 'ACcotsng 8nd Repth"rvJ by Ch8nt: Staltsnenl of R8¢Cfflmd0d Prath to tharilies pr8pariTrJ I¥ accounls In ith tho Fi1onLyal Reporti Standard aWicatAe in the UK and RepubM"c of Irel8nd IFRS 1021 lththe l Jarthry 3J191'. Fmanraal ReportirJ sdard 102 Tr Finanrial ReFKNts'rwJ Slw)dard aFf4KatrA8 in UK Republ¢ ol Irdand. th• Companies Act 2. Thefmantial statwnents have be prepared urtdsr th8 h'storical cosl con¥"r. FdlKul¥ Lnom0 FrJJn¢Jatrm is a ry6vate byguwantee. aThJ a wsterwj Golw eon¢ern The financial slatn•)t$ hav• be on a bass. The Tryes have revkwed and ¢onsIdej relev•nt infcfftwlim. indthlirJ the an buthjet snd Ire rAsh rn8k.ng thr 88se55menl. Based on these assewerls. 8TrJ Ihe rJt res¥C¢S avail•We. Ihe TnJ5tees have that Ihw ran Con"nl0 adoptthe wry Luem bass In ryepgthe amual rErt #rtd 8coJwtts. All ss rec¢9ned In the Statement ol Finaial kb'bitie5 once the ¢harty ha5 Wrtrtkxnemt to the fund5, It. proba14e that the be and th8 arTh)Lrt can be measured reliably. Liatrflfy'es are fectyThsed a exptrh1iiure as w as 1$ a 81 or c4rolru¥e 08"0n c4)mmitting the charity to ewditwe. it is pKtht4e tho1 • tr0ry5fer of e¢orAyni¢ knefits be reAty in sthm¢nl and the amount Lrf the ob1gati me85wed rd•. Eyndrlwe is 4¢roun1 for ffi on arvuals ba5E and has been d85sfi&1 undef Wdiros ltrt aegat all cr%1 ret to the cgory. Where CO$ be directly atknbuted lo partivJl hearys h8v¢ •l¢¢al¥J lo a¢tiths M a wN¢nt wbth the use of resourc8S. G15 to teen mel at the year thd ¢Yaie we as a cunmthent but not aU¢ •$ ywditur¢. trustee meelings 8Th1 the cc61d any al athKe on grern rnatter5. Tanglble nxed a55ets DoPrtciab"on is pr(V41d at th•ldkxiTrJ ann1 rates in Ordwto718 off 8Bch a888t over its eslwnated h. Computer fquiwnent 33% cffi ra1 Taxatlon The tharity ks exempt frun ttx on Ns trArltat4e Fund accounting Lknreskn"d&l fvnds can be used in aco)rthroJ ith tharilable otiectiVe5 at trdisc¥ebcffl olthe trtee$. Re5trictd funds ron only be uxd lerf pa.r re5trida purwses ithin the obj.ects Lrf the drity. Re5trcts"or 8ri% specThled by dorwutthen funds are raisèj Jr Pb.laT f8Sknded purposes. Fyrlhwe¥pknabw of Ihe nalwg pwpose fwKI 15 FrYJwJed inthe rXe5 b) thofirMJKA statWl. Hlrt purchase ièaslng commhmerts Rtsts under aptrairy Itasès are chwged to th• Slaemthit d Finanoal Adi%ilie8 on a straTrJht &n¢ th¢ piod ofthe lease. The ¢haiitsbl ¢thmp8ry op¥&tes a defined Culribulir pensKth sclme. cOrrtribions PAY8 to Ih ch"tat4e corrpanls p1( charged to th¢ 9otemwt of Financkal in th& PWk)d lo ralBIe. Page 15
Foll11•r L>Thphtyna F¢Jundatlon Ilotes Igthe Rnandal Slatem•nis- conllnued fortTre r•ftdert 31 December 2022 A¢¢ouniiThJ pol1de5-nt1nWId $lgnlll¢antludgernent aTrd estbNt•s Prepara'C ol the 51alements Ire5 to make styanffjcart judgements and e5tYnzt85 in d¢twrnThng the carlyj •nounts d ac¢ru8ls and deferred Man•Yent m8kes as5umF4ion5 Qf the OfftS cl urtan fr8 a¥ts on a6sets and liab"lrti86 at tho Sheet date. Th8 managen¢8 estimates and assurnpi are ba5•d ly'1¢¥ ev1ce and &weclatw fvture events and are rewewed pul0dlly. TP4s (b'sdosw& 8Xd utaty fvIL¥e events and Judent in res of measwng finantial instruments. Managnent do nrl oYAider th8nE 10 be ty mat&yW or esknab'cffj urKwtwnty requlri di8d3sur•. Flnanclal Instruments Finana81 assets and fir£ni¥ lablth"¢s we re¢¢$r1 in th¢ W•K¢ ¢h•rity becomes • p•rty lo the wnlraLthd prwgowts ¢rfthe 1ment olher Jebtors ond u&Jifors we da5sfiwJ as "¢ finw¥ instrum¥ts measw¢d at initial reLyyJnilwx al tr#n50¢b"th prica. Debtors creditu5 SubwUY mtyaswed at horftsad COSE using th• off8¢tive intwesl rate meth)d. A yo¥isicn is esiai41d tWe is (¥ethe Ihal Ihe be ¢10 cd all ¥mtturts due. Cash cash etymlents We dasslled •$ basic fjmnaal ¥8truments and C[1• cash in and at b8nk and bar ovwdralts are an int•Jal wlofthe Gh¥itw$ cash FInana liilib¢s Irtr is>A by Ihe chwty are classified in arx0rd8 wrth the subslance of the ¢ontracbj ent¥•Y into and defiritions of a finArwial lJ"at•"lty an equrty insbument. An equity instrument is any o)rtrxl Ihal thnrAs a re5ul irtwe5t in the assèts of the tharity after deducting al Of rts lah"lth"¥s. Eqitify instrum6ntS Issu bytha tharty are r¢cordwJ at the pro¢¢eds r4ved. not ol thr8ct issue Donatlons and Itya¢tes 2022 2021 Eh)nation¥ 1.678 785 Donations and legaLyes wK4ude resrrmJ irKane raved of£200,(W )r SL aThJ than¢eThI treatsne and reS fr* FL tht e5tailistrmt¥rt of a Paliurt FL Rw'5try and Bicbank. 2022 2021 DepJ5it ac¢tyJnt irtuest 37 PagB 16
Folllular LphornI Found#l¢)n Not5 tothe Anancl81 Statements. conllnued for the yeorended 31 Owmbtr 2022 Ral$•TrJ fvnd$ RalslThJ donalons and l•gaeles 2022 2021 Staff ¢osls Mwketing and CrynmunhinS Event Consultancy IT anL1 support co AJl(ATron 01eats Trovel Evenl eosls FUndraTra les 86,929 37,023 20.492 3.254 24.485 25.403 fj9. 4e9 20.659 1.304 10,966 318,566 106,992 Investhient m4nto¢ment ¢0gts 20 A9ty0gate amwnts 330,453 Chorflablt *¢Uvlll•s ¢0Sts CURE FL Olr•¢l grant C95ts Isee note ei Swrt costs l$e• ntste n Totals "rect Expendi GOvernae Gosts Support costs 736.834 B03.501 369.398 16,302 1.929,733 16.302 133,677 756.834 2079712 CURE FL qrnnt award 2022 2021 CLIRE FLF Grant aw•d CURE FL Man4gemt C4Jsts e03.501 232 294 1035.795 The iota gw15 paNI lo instthApxsdurirvJ Ihe yoar was a5 kn. 2022 2021 Gal (uThJ Pago 17
Follkwlaw LThpha F4yJThllon Not•s to Flrwidal alemwrt5. ¢ontlnu fortheyear endtd 31 DeeernLW 2022 Support Casts Other Totsfs Direct Expendiiwe 113,28n 16.302 369.398 16,302 986171 Support Costs 178.501 39.353 287 083 Net In¢omell•xidl1urnl Net Irwn(eWdrt¢j B led aftèr (MirWI(x•thbt¥Jl'. 2022 2021 Audit. remuneration 15.056 17.251 2.578 Hireof plant and 367 810 ded 31 De¢ber 2021. Trustees. expenses There wer• no truslee5' ewnses pgrd (or th• >w 31 0MbIT2022 nor for ywr ded 31 De¢¢mbtr 2021. Donatlons frorn Tru5t•qs' During Ihe pwiodtre agJwate •wuntoldmaknns trrffl Trustees £9.(W12021: £10.1)Jo}. 10. Staff costs Th• averaye Thmber OfoyeeS duri Ihe yearwa5 5{2W21-41. Th• aver4e number demrAoyÉes duriry tryèarwas a$fokn*" 2022 2021 Athnin 2021 eeQ.CQi- £70,¢X £70.W1 . £80,( .c()1- £9],( £101.C((1- £110.Q 18
Folllalar L)Thph¢m• Fwndlon Notes tolhe Fln•ndal Statements. ¢ontlnued forthe year endtd 31 Decemijer 2022 11. Tanglble fixed assets Computer equlpmnt Cosi At 1 January XQ2 ibms . 10.216 At 31 oKber 2022 14.816 Al 1 22 Charge f(year 4.520 3.263 At 31 Oe¢emt ZQ22 Nèt Ixok value At 31 Oecemtr 2022 7.033 Al 31 Oewnber 2021 5.696 11 Debtors: aM+)ts lallln9 due wllhln fft yew 20Z2 2021 Trndtr debtors Qlher debttys Prepayments and irthme s).ocKJ 20.346 11 Cr•dltor&' falllrffj •kn Tlthln year 2022 2021 Bank loans o¥erdraft5 I 14) Trade Cr11 16.401 211,334 25.135 17 851 14.833 9.449 21 438 l& Loans An ¥ty55 d the maturity cl kJa 15 belw. 2022 2021 rnwnts faling *thin¢Thyèar on Bank overdrafts Pwjb 19
Folll¢ulw Lnph1Tha Foundatlon Not05 to th• RnarKlal Statements.conllnued Tor the yearendea 31 De¢anbef 2022 Analjryls ol nèt assets betwi funds 2022 Totsl 2021 Total funds nd5 Fixed 855816 Ojrrent assets Current ab¢th"es 7,033 1,455.609 270.7211 5.696 1.439.249 {16.4011 1,439.208 1 191.921 16.401 1 175520 1.399.425 Movement In fund movwnent In lunds Al 111122 31112122 Unrestricttd General lund 1.399.425 I207.) 1,191.921 Restr¢ 118,4011 TOTAL FUNDS 1.399.425 223,9)51 1,175.520 Net mo¥ent irb fwds. irKWvJ n the abrye areas Idkx5." IrK¢mlng Resoure•s Mov•ment lTrfunds Unrestrlcted funds Gen¥al Ivnd 1,986.260 12.193.784) 1207,5041 R•strkted furrf Resrrid 1216.4011 116.4011 TOTAL FUNOS cOmra11¥•$ for mo¥•m•rt In funds Net mtrv¢ment In funds At 31M2121 At 111ll1 Unrestrl¢ted fvnds Gen¥al fvnd 356.337 1,043,088 1,399.425 TOTAL FUNDS 13425
F•lIkl¥ LyTnph•w F•und4lt Nths to the Flnaftdal Statembts. ¢OnllNed fortheyearended 31 Decemtxr2Q22 MoveThnt th funts-¢ontlnued In lund5 General fvjnd 1.678.822 1635.734} 1,043.088 TOTAL FUNDS 1.678.822 635.734 1,043.086 A current yew 12 Mont year 12 cryrt>vwd os t. Net movement In funds At 31n2Q2 At 111r21 G¥21 bJThJ 356.337 B35.584 1.191,W21 Re5tr1¢t•d lunds Reslrthj 116.4011 110.4011 TOTAL FUNDS A cwrent year 12 mtffilhs and year 12 mths n81 Eno1 In knds. inc4tyJ in thg are In funrts Unrestrlthd fund5 Gwwal fijnd 3.065.0tr2 12.e29.4981 835.584 R•stricied funds 2.Th?0 1216.4011 116.4011 TOTAL FiOs 819 183 17. Related partydsdo5ur•¥
FollknJlar L5Ph FoundOn TortYearended 31 Decemlxr 2022 18. Uablty ol mem15 charilatAe CLryany is lini1 by yrarte¢ and hos ¥1 tr* oftha dwi18tlo C¥Jnpany ny wound.up, the IAtiity in Ih• hmrt•J lo £10 w rnb of the charilae ctynpaThy during Ihe tine they are a rnwnber or year of ceasirg to be a rn¥nber. 85 Staled fft ihe Memorandurn •nd hjtidos ofA66ou'ation. Pape 22